Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Fostamatinib

Fostamatinib 100mg twice daily for 12 weeks

DRUG

Fostamatinib

Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12

DRUG

Fostamatinib

Fostamatinib 75mg twice daily for 12 weeks

DRUG

Fostamatinib

Fostamatinib 50mg twice daily for 12 weeks

DRUG

Placebo

Placebo twice daily for 12 weeks

Trial Locations (34)

Unknown

Research Site, New Territories

Research Site, Hong Kong

Research Site, Matsuyama

Research Site, Fukuoka

Research Site, Kitakyushu-shi

Research Site, Kurume

Research Site, Sapporo

Research Site, Kato-shi

Research Site, Kasama-shi

Research Site, Kumamoto

Research Site, Sendai

Research Site, Isahaya

Research Site, Nagasaki

Research Site, Omura-shi

Research Site, Sasebo-shi

Research Site, Shibata

Research Site, Okayama

Research Site, Tomigusuku-shi

Research Site, Matsue

Research Site, Hamamatsu

Research Site, Shinjuku

Research Site, tabashi City

Research Site, Anyang-si

Research Site, Gwangju

Research Site, Incheon

Research Site, Seoul

Research Site, Chiayi City

Research Site, Kaohsiung City

Research Site, Taichung

Research Site, Taipei

Research Site, Bangkok

Research Site, Singapore

Research Site, Hanoi

Research Site, Ho Chi Minh City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY